



COMSYS Clinical



Major Pharmaceutical Company Animal Health Division

CLIENT SITUATION

Founded in 1912, our client is a leading manufacturer and distributor of prescription and over-the-counter animal health care products for the livestock and companion animal industries. They serve the U.S. and international markets, distributing products in more than 100 countries. They currently rank first in veterinary vaccine sales in North America.

They produce a product for heartworm prevention in canine companion animals and wished to investigate adverse events following the drug's administration. Through partnerships with academia and veterinary hospitals, COMSYS Clinical reviewed and analyzed detailed veterinary encounter records for all pets at 500+ veterinary clinics nationwide. This unprecedented wealth of detailed, integrated information allowed our client to conduct studies which were previously impossible. The client wanted to track 800,000+ dogs and estimate the size of any potential associations of drug administration with subsequent adverse events such as disease or death.

COMSYS SOLUTION

The request from our client required advanced statistical analyses on this very large dataset in order to obtain the information needed and, in particular, to estimate any potential associations with rare events. All dogs receiving this heartworm medication over a period of five years were followed for 90 days following and any adverse events such as diseases and deaths were noted.

SAS software and logistic regression analysis were used to examine the relationships of preexisting conditions, covariates (age, gender, weight, neuter status, concurrent vaccine etc.) and the drug's administration on the rates of subsequent adverse events.

CLIENT BENEFITS

Our client reported the results of the study to the FDA as part of a presentation requesting reintroduction of the drug to the U.S. market. The wide extent of the study was important to the FDA in looking at as many scenarios as possible in evaluating the safety of the drug. This drug has subsequently been reintroduced to the U.S. market which has assured continued revenue to this client.

Do business. **We're IT.**